Keywords: Syntaxin, Ipsen, Collaboration, Botulinum-toxin therapeutics
Syntaxin and Ipsen in up to $99 million collaboration on novel botulinum-toxin therapeutics
Article | 21 October 2011
French drugmaker Ipsen (Euronext: IPN) has entered into a global strategic collaboration with privately-held UK biotech firm Syntaxin to explore ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
